Target Patient Population:Patients with a diagnosis of IgAN who have persistent proteinuria who remain at high risk of disease progression despite being on a stable prescribed regimen of RASi
Study Overview: Evaluate the effect of atacicept compared to placebo on change in proteinuria in adult subjects with IgAN
Study Timeline: Anticipated patient participation is 3.5 years, 21 visits to the clinic.
Number of Patients Currently Active in the Trial: 0
